NeoGenomics [NEO] vs Thermo Fisher [TMO] Detailed Stock Comparison
NeoGenomics
NASDAQ
Loading...
Thermo Fisher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: NeoGenomics wins in 8 metrics, Thermo Fisher wins in 10 metrics, with 0 ties. Thermo Fisher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | NeoGenomics | Thermo Fisher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -12.84 | 27.70 | NeoGenomics |
| Price-to-Book Ratio | 1.20 | 3.58 | NeoGenomics |
| Debt-to-Equity Ratio | 48.21 | 69.62 | NeoGenomics |
| PEG Ratio | -0.10 | 4.88 | NeoGenomics |
| EV/EBITDA | -164.14 | 19.41 | NeoGenomics |
| Profit Margin (TTM) | -15.10% | 15.24% | Thermo Fisher |
| Operating Margin (TTM) | -15.43% | 17.84% | Thermo Fisher |
| EBITDA Margin (TTM) | N/A | 17.84% | N/A |
| Return on Equity | -11.76% | 13.42% | Thermo Fisher |
| Return on Assets (TTM) | -3.25% | 4.97% | Thermo Fisher |
| Free Cash Flow (TTM) | $-34.04M | $7.27B | Thermo Fisher |
| Dividend Yield | N/A | 0.31% | N/A |
| 1-Year Return | -51.46% | -21.55% | Thermo Fisher |
| Price-to-Sales Ratio (TTM) | 1.49 | 4.19 | NeoGenomics |
| Enterprise Value | $1.28B | $209.98B | Thermo Fisher |
| EV/Revenue Ratio | 1.85 | 4.86 | NeoGenomics |
| Gross Profit Margin (TTM) | 42.61% | 40.61% | NeoGenomics |
| Revenue per Share (TTM) | $5 | $114 | Thermo Fisher |
| Earnings per Share (Diluted) | $-0.82 | $17.31 | Thermo Fisher |
| Beta (Stock Volatility) | 1.62 | 0.76 | Thermo Fisher |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
NeoGenomics vs Thermo Fisher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| NeoGenomics | -4.56% | -0.25% | 30.92% | 7.71% | -22.19% | -51.73% |
| Thermo Fisher | -2.43% | -2.67% | 0.43% | 15.44% | -6.47% | -8.25% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| NeoGenomics | -51.46% | -20.16% | -77.78% | 12.27% | 643.93% | 2,387.50% |
| Thermo Fisher | -21.55% | -11.42% | 11.75% | 281.19% | 913.44% | 1,454.17% |
News Based Sentiment: NeoGenomics vs Thermo Fisher
NeoGenomics
News based Sentiment: MIXED
NeoGenomics experienced a volatile month with a major legal victory offset by disappointing financial results and a securities fraud investigation. While the patent win is a positive catalyst, the financial concerns and investigation create significant uncertainty, making this a mixed story for investors.
Thermo Fisher
News based Sentiment: POSITIVE
September was a strong month for Thermo Fisher Scientific, driven by better-than-expected earnings, raised guidance, and significant acquisitions. While margin concerns exist, the overall narrative is positive, indicating continued growth and value creation for investors. Analyst upgrades and institutional investment further support a favorable outlook.
Performance & Financial Health Analysis: NeoGenomics vs Thermo Fisher
| Metric | NEO | TMO |
|---|---|---|
| Market Information | ||
| Market Cap | $1.03B | $181.05B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 3,688,010 | 1,482,320 |
| 90 Day Avg. Volume | 2,608,390 | 1,767,880 |
| Last Close | $7.96 | $479.46 |
| 52 Week Range | $4.72 - $19.11 | $385.46 - $623.77 |
| % from 52W High | -58.35% | -23.14% |
| All-Time High | $61.57 (Feb 15, 2021) | $672.34 (Dec 27, 2021) |
| % from All-Time High | -87.07% | -28.69% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.10% | 0.03% |
| Quarterly Earnings Growth | 0.10% | 0.05% |
| Financial Health | ||
| Profit Margin (TTM) | -0.15% | 0.15% |
| Operating Margin (TTM) | -0.15% | 0.18% |
| Return on Equity (TTM) | -0.12% | 0.13% |
| Debt to Equity (MRQ) | 48.21 | 69.62 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.64 | $133.77 |
| Cash per Share (MRQ) | $1.27 | $16.92 |
| Operating Cash Flow (TTM) | $14.05M | $7.58B |
| Levered Free Cash Flow (TTM) | $4.77M | $5.18B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.31% |
| Last 12-Month Dividend | N/A | $1.21 |
Valuation & Enterprise Metrics Analysis: NeoGenomics vs Thermo Fisher
| Metric | NEO | TMO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -12.84 | 27.70 |
| Forward P/E | 39.80 | 20.41 |
| PEG Ratio | -0.10 | 4.88 |
| Price to Sales (TTM) | 1.49 | 4.19 |
| Price to Book (MRQ) | 1.20 | 3.58 |
| Market Capitalization | ||
| Market Capitalization | $1.03B | $181.05B |
| Enterprise Value | $1.28B | $209.98B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.85 | 4.86 |
| Enterprise to EBITDA | -164.14 | 19.41 |
| Risk & Other Metrics | ||
| Beta | 1.62 | 0.76 |
| Book Value per Share (MRQ) | $6.64 | $133.77 |
Financial Statements Comparison: NeoGenomics vs Thermo Fisher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NEO | TMO |
|---|---|---|
| Revenue/Sales | $168.04M | $10.36B |
| Cost of Goods Sold | $94.79M | $6.13B |
| Gross Profit | $73.25M | $4.24B |
| Research & Development | $10.18M | $342.00M |
| Operating Income (EBIT) | $-27.83M | $1.82B |
| EBITDA | $-6.31M | $2.73B |
| Pre-Tax Income | $-25.66M | $1.62B |
| Income Tax | $266,000 | $95.00M |
| Net Income (Profit) | $-25.92M | $1.51B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NEO | TMO |
|---|---|---|
| Cash & Equivalents | $346.19M | $4.13B |
| Total Current Assets | $573.93M | $23.38B |
| Total Current Liabilities | $279.70M | $13.17B |
| Long-Term Debt | $400.58M | $31.37B |
| Total Shareholders Equity | $888.27M | $49.49B |
| Retained Earnings | $-351.70M | $54.45B |
| Property, Plant & Equipment | $366.10M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NEO | TMO |
|---|---|---|
| Operating Cash Flow | $735,000 | $2.15B |
| Capital Expenditures | $-4.50M | $-350.00M |
| Free Cash Flow | $-29.83M | $361.00M |
| Debt Repayment | N/A | $-838.00M |
| Common Stock Repurchase | N/A | $-2.00B |
Short Interest & Institutional Ownership Analysis
| Metric | NEO | TMO |
|---|---|---|
| Shares Short | 5.23M | 3.94M |
| Short Ratio | 1.67 | 1.95 |
| Short % of Float | 0.06% | 0.01% |
| Average Daily Volume (10 Day) | 3,688,010 | 1,482,320 |
| Average Daily Volume (90 Day) | 2,608,390 | 1,767,880 |
| Shares Outstanding | 128.15M | 380.77M |
| Float Shares | 119.99M | 376.74M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 1.00% | 0.92% |
Dividend Analysis & Yield Comparison: NeoGenomics vs Thermo Fisher
| Metric | NEO | TMO |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.21 |
| Last 12-Month Dividend Yield | N/A | 0.31% |
| 3-Year Avg Annual Dividend | N/A | $1.33 |
| 3-Year Avg Dividend Yield | N/A | 0.07% |
| 3-Year Total Dividends | N/A | $3.99 |
| Ex-Dividend Date | N/A | Mar 14, 2025 |